Skip to main content
Fig. 2 | BMC Medicine

Fig. 2

From: A new histone deacetylase inhibitor remodels the tumor microenvironment by deletion of polymorphonuclear myeloid-derived suppressor cells and sensitizes prostate cancer to immunotherapy

Fig. 2

CN133 may improve anti-tumor effect by augment of immunity function. A Growth curve of RM1 prostate cancer subcutaneous tumors in immunodeficient BALB/c mice treated with placebo or low dose CN133 treatment. B Growth curve of RM1 prostate cancer subcutaneous tumors in immunocompetent C56BL/6 J mice treated with placebo or low dose CN133 treatment. C Microarray data from CN133 treatment (n = 3) and placebo tumor tissues (n = 3) in the xenograft C56BL/6 J mice were applied to identify differential genes between those two groups. D KEGG pathway enrichment analysis showed top 10 significantly different pathways in the CN133 treatment group relative to the placebo group. E Volcano plots showing different genes from RNA-seq data. F MDSC regulation cytokines were tested in the xenograft C56BL/6 J tumor tissues by RT-qPCR

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us